Oaktree Acquisition III Life Sciences Warrant (OACCW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OACCW SEC filings page.
This page shows Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 figures portray an acquisition vehicle whose reported earnings did not come from recurring operating cash generation.
The reported$7.3M net income sits beside a$1.2M operating loss and operating cash flow of-$422K , indicating earnings were not produced by recurring operations.
At FY2025 end, liabilities of
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Oaktree Acquisition Corp. III Life Sciences Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
For every $1 of reported earnings, Oaktree Acquisition Corp. III Life Sciences Warrant used $0.06 of operating cash (-$422K OCF vs $7.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Oaktree Acquisition Corp. III Life Sciences Warrant reported $1.6M in net income in Q2 2026. This represents a decrease of 14.4% from the same quarter a year earlier. Against the prior quarter it is up 15.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Oaktree Acquisition Corp. III Life Sciences Warrant held $1.2M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
OACCW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, EBITDA, Interest Expense, Income Tax, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
OACCW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $206.5M+3.7% | $204.8M+3.8% | $203.1M+4.0% | $201.2M | $199.2M | $197.2M | $195.3M | N/A |
| Current Assets | $1.3M-19.3% | $1.4M-4.5% | $1.5M-0.6% | $1.5M | $1.6M | $1.5M | $1.6M | N/A |
| Cash & Equivalents | $1.2M-14.8% | $1.3M-0.4% | $1.4M+5.7% | $1.3Mn/m | $1.4M | $1.3M | $1.4M | $0 |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 | $0 |
| Total Liabilities | $214.0M+4.0% | $212.1M+4.1% | $209.9M+4.3% | $208.0M | $205.7M | $203.8M | $201.3M | N/A |
| Current Liabilities | $1.7M+54.6% | $1.6M+53.4% | $1.3M+78.7% | $1.2M | $1.1M | $1.1M | $727K | N/A |
| Non-Current Liabilities | $212.3M+3.8% | $210.4M+3.8% | $208.6M+4.0% | $206.8M | $204.6M | $202.7M | $200.6M | N/A |
| Total Equity | -$7.5Mn/m | -$7.2Mn/m | -$6.8Mn/m | -$6.8Mn/m | -$6.5M | -$6.5M | -$6.1M | -$23K |
| Retained Earnings | -$7.5Mn/m | -$7.2Mn/m | -$6.8Mn/m | -$6.8M | -$6.5M | -$6.5M | -$6.1M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
OACCW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
OACCW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$6.8M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Oaktree Acquisition Corp. III Life Sciences Warrant OACCW | FY2025 | N/A | $7.3M | N/A | N/A | — |
| Oaktree Acquisition Corp. III Life Sciences Unit OACCU | FY2025 | N/A | $7.3M | N/A | N/A | — |
Where Oaktree Acquisition Corp. III Life Sciences Warrant Ranks
Frequently Asked Questions
Is Oaktree Acquisition Corp. III Life Sciences Warrant profitable?
Yes, Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) reported a net income of $7.3M in fiscal year 2025.
What is Oaktree Acquisition Corp. III Life Sciences Warrant's operating cash flow?
Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) recorded an outflow of $422K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Oaktree Acquisition Corp. III Life Sciences Warrant's total assets?
Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) had $203.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Oaktree Acquisition Corp. III Life Sciences Warrant's current ratio?
Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) had a current ratio of 1.19 as of fiscal year 2025, which is considered adequate.
What is Oaktree Acquisition Corp. III Life Sciences Warrant's return on assets (ROA)?
Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) had a return on assets of 3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Oaktree Acquisition Corp. III Life Sciences Warrant's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) held $1.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $422K over that year. Dividing the one by the other, the reported balance equals about 41 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Oaktree Acquisition Corp. III Life Sciences Warrant's debt-to-equity ratio negative or not reported?
Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) has negative shareholder equity of -$6.8M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Are Oaktree Acquisition Corp. III Life Sciences Warrant's earnings high quality?
For every $1 of reported earnings, Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW) used $0.06 of operating cash (-$422K OCF vs $7.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.